Similar articles

• FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.

  Chuang-Stein C, Beltangady M. Chuang-Stein C, et al. J Biopharm Stat. 2010 Nov;20(6):1143-9. doi: 10.1080/10543406.2010.514456. J Biopharm Stat. 2010. PMID: 21058110
• Introduction to discussion papers on draft FDA guidance on adaptive designs.

  Chang M. Chang M. J Biopharm Stat. 2010 Nov;20(6):1113-4. doi: 10.1080/10543406.2010.514448. J Biopharm Stat. 2010. PMID: 21058106 No abstract available.
• Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.

  Gallo P, Anderson K, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Gallo P, et al. J Biopharm Stat. 2010 Nov;20(6):1115-24. doi: 10.1080/10543406.2010.514452. J Biopharm Stat. 2010. PMID: 21058107
• Review of draft FDA adaptive design guidance.

  Cook T, DeMets DL. Cook T, et al. J Biopharm Stat. 2010 Nov;20(6):1132-42. doi: 10.1080/10543406.2010.514455. J Biopharm Stat. 2010. PMID: 21058109 Review.
• Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.

  Bottomley A, Jones D, Claassens L. Bottomley A, et al. Eur J Cancer. 2009 Feb;45(3):347-53. doi: 10.1016/j.ejca.2008.09.032. Epub 2008 Nov 14. Eur J Cancer. 2009. PMID: 19013787 Review.